What Cifespasmo Treats: Main Uses and Benefits

Antispasmodic medications are commonly used for symptomatic relief in conditions marked by heightened physiological activity. Cifespasmo is generally used in areas where short-term symptom management is appropriate and where symptoms create noticeable physiological strain. It is relevant for easing symptoms related to acute episodes across several areas, including the gastrointestinal, biliary, and urinary systems.

This medication is applied across domains where additional symptomatic support is needed to address symptom clusters that may become intense or disruptive. It is commonly used to help with conditions presenting with acute episodes and symptoms related to physical discomfort, such as intestinal colic, biliary colic, and renal colic (associated with kidney stones). One of the main benefits is offering symptomatic relief that helps patients cope more steadily with difficult episodes.

“This medication is applied during phases when symptoms become more noticeable, offering additional symptomatic support.”

It may assist with maintaining functional stability and supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Spasms

Cifespasmo is commonly used to help with symptoms related to heightened physiological activity, such as acute pain and spasms of the digestive tract.

Cifespasmo's population eligibility is strictly defined by regulatory documents, primarily based on the risk of anticholinergic complications. The medicine is absolutely contraindicated in several populations. These formal contraindications include myasthenia gravis, untreated narrow-angle glaucoma, megacolon, paralytic or obstructive ileus, and mechanical stenosis in the gastrointestinal tract. Use is also prohibited in patients with prostatic hypertrophy with urinary retention and those with tachycardia or known hypersensitivity to Hyoscine Butylbromide.

Eligibility Limitation	Status
Age under 6 years	Safety and efficacy not established.
Pregnancy/Lactation	Not recommended (Limited safety data).
Cardiac Conditions	Requires caution (Risk of increased heart rate).
Hepatic/Renal Impairment	Requires caution (Risk-benefit consideration).

The medication is generally established for adults and adolescents over 12 years. However, official labels advise caution for patients with pre-existing cardiac conditions and those with pyrexia (fever). For patients with impaired hepatic or renal function, use requires careful risk-benefit consideration. The official status for use during both pregnancy and lactation is not recommended, due to insufficient data to establish safety.

Interactions with other medicines and products

Official regulatory information describes several documented interaction patterns for Cifespasmo (Hyoscine Butylbromide), which are primarily based on its anticholinergic properties and impact on gastrointestinal (GI) motility.

---

Documented Interaction Patterns

Interacting Medicine Category	Official Effect Description
Other Anticholinergics	The anticholinergic effects may be intensified or enhanced by Cifespasmo. This includes tricyclic antidepressants, antihistamines, and quinidine.
Dopamine Antagonists	Concomitant treatment may result in the diminution of the effects of both medicines on the GI tract (e.g., metoclopramide).
Beta-Adrenergic Agents	The tachycardic effects (increased heart rate) may be enhanced.
Other Oral Medications	Cifespasmo can delay the systemic absorption and pharmacological effects of other medicines taken by mouth, due to reduced GI motility.

---

Restrictions and Specific Cautions

• Route-Specific Contraindication: The intramuscular injection of Cifespasmo is formally contraindicated in patients receiving anticoagulant drugs due to the documented risk of intramuscular haematoma.
• Timing Requirement: Regulatory information advises that Cifespasmo should be administered at least one hour before other oral medications to manage potential delayed absorption.
• Population Note: For the parenteral form, the associated adverse reactions of tachycardia may be more severe or serious in patients with underlying cardiac conditions (e.g., coronary heart disease or hypertension).

Antispasmodic Mechanism (Pharmacodynamics)

Cifespasmo (Hyoscine Butylbromide) functions as a competitive antagonist primarily targeting muscarinic acetylcholine receptors ( M1, M2, M3) on visceral smooth muscle. The drug physically blocks the binding site, inhibiting the natural excitatory signal transmitted by acetylcholine (ACh) from the parasympathetic nervous system. This molecular blockade disrupts the subsequent Gq-protein signaling cascade, which is essential for initiating muscle contraction. The downstream consequence is a reduction in the release and influx of intracellular calcium ions (Ca^2+), the critical molecular step required to activate the contractile apparatus within the muscle fibers. This targeted cellular effect leads directly to smooth muscle myorelaxation and yields a spasmolytic physiological effect. Due to its quaternary ammonium compound structure, the drug is restricted to the peripheral nervous system, concentrating its antispasmodic mechanism on the smooth muscle of the gastrointestinal and genito-urinary tracts, resulting in the modulation of hyper-motility without affecting central nervous system pathways.

Cifespasmo (Hyoscine Butylbromide) is administered via both oral and parenteral routes, depending on the required speed of action and the clinical context. The medication is formulated as an oral tablet (10 mg and 20 mg strengths) and as a sterile solution for injection (20 mg per milliliter). The parenteral route, which includes intravenous (IV), intramuscular (IM), and subcutaneous (SC) injection, is typically reserved for acute episodes where a rapid response is necessary.

For adults and adolescents over 12 years, the standard oral regimen is 10 mg to 20 mg, administered up to four times daily. The dose for injection is 20 mg to 40 mg, which may be repeated after 30 minutes, provided the total daily dose does not exceed the maximum of 100 mg. Administration logistics are highly specified: tablets must be swallowed whole with water and may be taken irrespective of food intake. Intravenous injection must be administered slowly. Furthermore, the IM route is generally restricted in patients receiving anticoagulant therapy, with IV or SC routes used as alternatives.

The medication is intended strictly for short-term use and should not be taken on a continuous daily basis. Prolonged, uninterrupted administration without a medical investigation of the underlying cause of symptoms is discouraged. A pediatric oral dosing schedule for children aged 6 to 12 years is also defined, specifying one 10 mg tablet, three times daily.

Research Evidence / Overview of Studies for Cifespasmo

This overview describes the types of research that have been conducted for Cifespasmo (Hyoscine Butylbromide) and explains what is known and what remains uncertain about its use, using language that avoids clinical advice or promises of certainty.

---

Evidence Structure for Gastrointestinal Spasms

Research has examined contexts in which Cifespasmo was used for conditions involving acute, painful contractions of the smooth muscles in the gut. Studies often included short-term randomized controlled trials (RCTs) and systematic reviews that have examined how symptoms of acute pain and cramping changed during the study period.

These studies monitored patient-reported outcomes describing perceived discomfort and used measures like pain scores to evaluate how individuals experienced symptoms during periods of increased symptom activity. Studies report how symptoms evolved in the observed populations, describing patient-reported changes in cramping and acute discomfort.

The available research primarily focuses on short-term symptom management during acute events. Consequently, there is limited information for long-term outcomes when the medicine was observed in continuous use. Also, results apply only to the populations studied, which were typically adults with acute, symptomatic spasms, meaning data for certain groups remain insufficient.

---

Evidence Structure for Acute Colic Episodes

Research explored the use of Cifespasmo as an intervention in conditions associated with acute or disruptive episodes, including spasms that occur in the intestine, bile ducts, and urinary tract. This research examined its application in research scenarios where symptoms become more noticeable and may lead to functional limitations.

Focus on Intestinal Colic Research

Studies conducted during periods of increased symptom activity, such as intestinal colic, studies monitored outcomes related to systemic or functional imbalance. Research was observed in trials assessing short-term or episodic symptom patterns, where outcomes related to physical discomfort and the need for rescue pain medication were measured during the study period. The findings describe patterns observed in the studies related to the patient-reported outcomes describing perceived discomfort during these acute episodes.

Focus on Biliary and Renal Colic Research

Evidence was evaluated in studies focused on acute abdominal pain originating in the biliary system and the urinary tract, specifically for biliary colic and renal colic (associated with kidney stones). In these contexts, research explored outcomes capturing phases of heightened symptom activity, such as severe cramping pain. Findings described the medicine’s application in research contexts involving outcomes related to physical discomfort, but in some cases, the comparative evidence is lacking against other types of analgesics commonly used for conditions like renal colic.

Key Studies & References

1. Hyoscine butylbromide mode of action on bowel motility: From pharmacology to clinical practice (2023 Review)
2. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis
3. Public Assessment Report: Butylscopolamine bromide RIA 10 mg film-coated tablets (hyoscine butylbromide) - Scientific discussion

Common questions about Cifespasmo (FAQ)

Q: How quickly does Cifespasmo start working after you take it?

A: After taking Cifespasmo orally, the time it takes for the medicine to be absorbed and reach its peak level in the bloodstream is typically about two hours. The medicine is designed to quickly concentrate its action on the smooth muscles of the gut shortly after absorption, though the effects are generally expected shortly after absorption.

Q: Does Cifespasmo cause drowsiness or fatigue?

A: Official information indicates that Cifespasmo can rarely cause side effects such as drowsiness or sleepiness. Other effects on the nervous system, including dizziness or temporary confusion, have also been reported. Caution is advised if patients experience drowsiness or dizziness when performing tasks that require concentration.

Q: Can Cifespasmo be taken with over-the-counter pain relievers like paracetamol?

A: While regulatory documents do not specifically name paracetamol (acetaminophen), Cifespasmo can slow down the speed at which other medicines taken by mouth are absorbed into the body. To minimize this potential interaction, patients are advised to consult a healthcare professional regarding specific combinations.

Q: How long do the effects of Cifespasmo usually last?

A: The effects of Cifespasmo are generally considered short-acting. Information on how the body breaks down the medicine suggests that the effects can last several hours, which is consistent with its typical usage for acute, short-term symptoms.

Q: Does Cifespasmo interact with common anxiety or depression medications?

A: Cifespasmo is known to interact with other medicines that have anticholinergic properties, such as those in the tricyclic antidepressant class, which can intensify side effects. Patients taking these medications are advised to consult a healthcare professional regarding potential interactions.

Q: Can I take Cifespasmo if I have high blood pressure?

A: Caution is recommended for people with pre-existing cardiac conditions, including high blood pressure (hypertension). This is because Cifespasmo can potentially increase heart rate. It is important that patients share their full medical history, including any heart conditions, with their healthcare provider.

Q: Is there any research on Cifespasmo's effectiveness for IBS (Irritable Bowel Syndrome)?

A: Yes, regulatory authorities have approved Cifespasmo for the symptomatic relief of Irritable Bowel Syndrome (IBS). It is also indicated for the relief of spasms in the gut and the genito-urinary tract.

Q: Can Cifespasmo be taken on an empty stomach?

A: Official product information states that the tablets can be swallowed whole with water and may be taken irrespective of whether the patient has eaten or not.

Q: Is Cifespasmo safe for older people (seniors)?

A: Caution is needed when Cifespasmo is administered to elderly patients. This is due to a potentially increased risk of side effects, particularly temporary confusion or dizziness, which may potentially increase the risk of falls.

Q: Are there any known food or drink interactions with Cifespasmo?

A: Official warnings recommend avoiding alcohol while using Cifespasmo, as alcohol can increase the chance of experiencing side effects such as drowsiness. The tablets may generally be taken regardless of food.

Q: Can Cifespasmo be taken long-term?

A: Cifespasmo is generally not intended for long-term use and is designated for short-term management of acute symptoms. Regulatory warnings state that prolonged, regular use is discouraged without a full medical investigation into the cause of the pain.

Q: What ingredients are in Cifespasmo?

A: The active pharmaceutical ingredient listed in the product information is Hyoscine Butylbromide. In addition to this main substance, the tablets contain various inactive ingredients such as sucrose, talc, and povidone.

Q: Why do some people say Cifespasmo helps with gas and bloating?

A: Cifespasmo is a spasmolytic drug, meaning it relaxes the smooth muscles of the digestive tract. By reducing the excessive contractions and regulating gut motility, the medicine may assist in alleviating the discomfort and symptoms associated with gas and bloating.

Q: Can children take Cifespasmo?

A: Cifespasmo is generally approved for use in adults and adolescents over 12 years of age. A specific, lower dosing schedule is also defined for children aged 6 to 12 years. Use is not recommended in children under the age of 6.

Q: What should I do if a side effect of Cifespasmo feels severe?

A: If severe pain persists, immediate medical attention should be sought. Furthermore, symptoms like fever, nausea, vomiting, or blood in the stool are potential warnings of a more serious underlying condition that requires professional evaluation.

Q: Can Cifespasmo be taken during pregnancy or while breastfeeding? (Informational)

A: The safety of Cifespasmo during pregnancy and lactation has not been established due to limited clinical data. The medicine is generally not recommended for use unless a healthcare professional determines the benefit outweighs the risk.

Q: Is Cifespasmo effective for stomach spasms not related to IBS?

A: Yes, Cifespasmo is indicated for the relief of painful spasms that occur throughout the gastro-intestinal tract. This indication is not limited only to symptoms associated with Irritable Bowel Syndrome.

Q: What is the recommended storage temperature for Cifespasmo?

A: Cifespasmo should be stored at Controlled Room Temperature, which is typically defined as 20 C to 25 C. It is also important that the medicine is protected from moisture and light.

Q: Has Cifespasmo been approved by major health organizations?

A: Yes, the active ingredient in Cifespasmo (Hyoscine Butylbromide) is a well-established medicine that has received approval from major governmental health authorities around the world for treating gastrointestinal and genito-urinary spasms.

Q: What makes Cifespasmo a prescription-only drug in some places?

A: The requirement for a prescription in many regions is related to the drug's anticholinergic properties and the potential for side effects in certain high-risk patient groups. This regulatory status helps ensure that the use of the medicine is supervised by a healthcare professional.

Q: How is the action of Cifespasmo different from a regular muscle relaxant?

A: Cifespasmo is specifically a smooth muscle relaxant that targets the involuntary muscles in the gut and urinary tract. This action differs from regular skeletal muscle relaxants, which act on voluntary muscles and may have broader effects on the central nervous system.

Q: Is Cifespasmo known to cause allergic reactions?

A: Yes, like many medications, Cifespasmo may cause hypersensitivity or allergic reactions. Reactions can range from mild symptoms like a rash or hives to rare instances of severe, life-threatening allergic reactions (anaphylaxis).

Q: Why is Cifespasmo sometimes called a 'gut relaxer'?

A: The term 'gut relaxer' is commonly used because it describes the medicine's main function. Cifespasmo works to relax the smooth muscles in the walls of the stomach and intestines, helping to alleviate painful contractions and spasms.

Q: Can I take Cifespasmo with antacids?

A: Cifespasmo has the potential to delay the absorption of other oral medications, including antacids. To ensure that both medicines work as intended, a healthcare professional may recommend taking them at separate times.

Q: Are there different forms of Cifespasmo (e.g., tablet, liquid)?

A: Cifespasmo is commonly available as an oral tablet for routine use and a sterile solution for injection for acute conditions. A liquid form for oral use may be manufactured and supplied in some specific regions.

Q: How soon after stopping Cifespasmo do the side effects go away?

A: The length of time required for the body to eliminate Cifespasmo is several hours. Once the medicine is fully cleared from your system, typically within 1–2 days, any side effects related to the concentration of the drug in the body should subside.

Q: Is it safe to drink alcohol while using Cifespasmo? (Informational)

A: Official regulatory warnings generally recommend avoiding alcohol while taking Cifespasmo. Alcohol can increase the chance of experiencing certain side effects, such as drowsiness, which can impact daily activities.

Q: Can Cifespasmo help with gallbladder pain or spasms?

A: Cifespasmo is indicated for the relief of spasms associated with the biliary tract. This means it may be used to help manage the painful contractions characteristic of conditions like biliary colic, which are related to the gallbladder system.

Q: Are there long-term health consequences from taking Cifespasmo regularly?

A: The drug is designated for short-term, acute use. Prolonged, regular use is discouraged by regulatory bodies without a proper medical diagnosis, as information regarding the long-term effects of continuous use is limited.

Q: Does Cifespasmo have an effect on bladder spasms?

A: Yes, Cifespasmo is indicated for the relief of painful spasms that occur in the smooth muscles of the genito-urinary tract. This includes symptoms related to functional bladder spasms.

Q: Can Cifespasmo be crushed or chewed?

A: Official product information states that the tablets should be swallowed whole with water. They should not be broken, crushed, or chewed, as altering the tablet can affect the intended absorption of the medicine.

How to Store and Dispose of Cifespasmo

Storage Requirements

Cifespasmo (assuming a solid dosage form) must be stored at Controlled Room Temperature, typically 20 C to 25 C. It is mandatory to keep the medicine in its original, tightly closed container and protect it from both moisture and excessive heat; do not freeze the product. Always ensure the medicine is kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Do not dispose of Cifespasmo by flushing it down a toilet or pouring it into a drain, as this can pose environmental risks. Unused or expired medication must be taken to an official drug take-back location or authorized pharmaceutical waste collection program. Disposal must adhere strictly to local and governmental pharmaceutical waste regulations.